Technological projects portfolio

Staphylococcus aureus infections are a major public health problem worldwide, and particularly the case of infections following surgery.

Postoperative Staphylococcus aureus infections may be severe and involve multiple methicillin-resistant strains (MRSA strains). In more than 80% of cases, the infection is related to the presence of Staphylococcus aureus in the patient’s nose (nasal colonization).

Nasal decolonization measures currently use antibiotics, but resistance rapidly emerges and the drugs are not applicable on a wide scale.

NASOFLORE is an LBP (live biotherapeutic product) composed of bacteria taken from the human nasal flora that have a strong inhibitive effect on Staphylococcus aureus, including the multi-resistant strains of MRSA.

The goal of NASOFLORE is to fight against nasal colonization of Staphylococcus aureus and naturally prevent self-infection caused by this germ.

It is the first example of an LBP targeting the nasal carriage of Staphylococcus aureus. Easy to use, NASOFLORE can prevent postoperative infection without the use of antibiotics.

Patients undergoing joint replacement surgery are the first target group for NASOFLORE.

More than 10 million people around the world have had a joint replacement and that number is expected to quadruple by 2030.

Staphylococcus aureus is the cause of more than 2000 joint replacement infections in France each year and these infections require significant medical and surgical treatment, generating excessive cost overages.

Despite great progress in the ways patients are treated, the prevalence of these infections is not going down. The Nasoflore approach represents a real source of hope for the future.